Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company’s net loss was $11.207 million, compared to $11.726 million for the corresponding period in 2016. The decrease in net loss is mainly attributable to the decrease in clinical study expense for both Sollpura and blisibimod in 2017. Loss from operations was $10.604 million against $11.717 million a year ago. Net loss applicable to common stockholders was $13.710 million or $2.03 per basic and diluted share against $11.726 million or $2.34 per basic and diluted share a year ago.